{'fraction_non_alphanumeric': 0.014874915483434753, 'fraction_numerical': 0.0067613252197430695, 'mean_word_length': 5.63677130044843, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Experience gained with Solcoseryl as treatment of patients with cerebral hemorrhage].

It is constrictive-stenotic arteriopathy developing in the remote period together with delayed ischemic affliction of the brain resulting in formation of persistent neurological deficit, disability of the patient or fatality that is regarded as the most important pathogenetic mechanism of unfavourable functional and vital prognosis of cerebral hemorrhage. Examined in the trial were 350 patients presenting with cerebral hemorrhage induced by rupture of the brain arterial aneurysms. 300 patients were treated with the drug preparation solcoseryl, 50 patients were the control group. A clinical and paraclinical monitoring of the state of the patients was conducted with the aid of an X-ray computerized tomography, ultrasound dopplerography of the extra- and intracranial arteries. A positive effect is shown of the drug on the risk of development of a clinically manifested neurological deficit that does not undergo regression against the background of paraclinically recordable objective signs of constrictive-stenotic arteriopathy and formation of unfavourable (gross disability, vegetative state, fatality) outcome as per the Glasgow Scale of Outcomes and a low level of the functional activity according to the Barttel's index at day 30 following the development of hemorrhage. The drug is well-tolerated and can be recommended in the treatment of aneurysmatic cerebral hemorrhages.